Table 3.
Percentage of Ab-positive women at delivery
| Primigravidae | Multigravidae | |||||
|---|---|---|---|---|---|---|
| Before IPT, N = 18 | After IPT, N = 28† | P* | Before IPT, N = 73 | After IPT, N = 86† | P* | |
| AMA1 3D7 | 94 | 100 | 0.390 | 99 | 99 | 1.000 |
| MSP1 3D7 | 89 | 96 | 0.552 | 99 | 99 | 1.000 |
| MSP2 3D7 | 89 | 96 | 0.552 | 97 | 98 | 1.000 |
| DBL1 3D7 | 0 | 7 | 0.513 | 11 | 32 | 0.002‡ |
| DBL1 7G8 | 0 | 11 | 0.270 | 0 | 18 | < 0.0001‡ |
| DBL1 + 2 FCR3 | 17 | 7 | 0.366 | 27 | 25 | 0.857 |
| DBL2 FCR3 | 0 | 0 | – | 10 | 9 | 1.000 |
| DBL3 7G8 | 44 | 21 | 0.115 | 79 | 64 | 0.053 |
| DBL3 A4 FCR3 | 44 | 18 | 0.092 | 73 | 57 | 0.049 |
| DBL3 FCR3 | 33 | 11 | 0.124 | 45 | 38 | 0.421 |
| DBL4 7G8 | 33 | 7 | 0.042 | 70 | 51 | 0.016 |
| DBL4 FCR3 | 17 | 4 | 0.284 | 32 | 30 | 0.864 |
| DBL4 IT4 | 22 | 18 | 0.721 | 55 | 40 | 0.081 |
| DBL5 3D7 | 61 | 32 | 0.072 | 88 | 79 | 0.205 |
| DBL5 7G8 | 83 | 50 | 0.030 | 95 | 85 | 0.071 |
| DBL5 FCR3 | 78 | 36 | 0.007 | 92 | 84 | 0.156 |
| DBL6 FCR3 | 22 | 4 | 0.069 | 56 | 26 | 0.000 |
| FV2 FCR3 | 61 | 29 | 0.037 | 88 | 74 | 0.030 |
Ab = antibody; DBL = Duffy antigen-binding ligand; FV2 = full-length VAR2CSA; IPT = intermittent preventive treatment. Bold values represent those that are significant (P < 0.05).
*
Fisher's exact t test. Cutoff s for seropositivity for each FV2-associated antigen was based on mean + 2SD of Ab levels in sympatric males; cutoffs for merozoite antigens were the mean + 2SD of Ab data for U.S. adults. Bolded P values indicate domains that were significant after controlling for false discovery rate at 5%.
†
Percentage calculated based on the delivery or last samples in the third trimester for women who had taken sulfadoxine–pyrimethamine.
‡
Prevalence increased.